期刊文献+

组蛋白去乙酰化酶-2与慢性阻塞性肺疾病的糖皮质激素治疗 被引量:2

下载PDF
导出
摘要 慢性阻塞性肺疾病(COPD)的气流受限为不完全可逆性,病变呈进行性加重。糖皮质激素的治疗作用一直是临床关注的热点。近年来组蛋白去乙酰化酶-2(Histonedeacetylases,HDAC-2)在气道炎症性疾病中的作用逐渐受到关注,其不仅参与COPD的发病过程,还影响糖皮质激素的疗效。对HDAC-2的深入研究将为COPD的治疗特别是提高激素的疗效提供新的理论基础。
出处 《上海医学》 CAS CSCD 北大核心 2011年第3期240-242,共3页 Shanghai Medical Journal
基金 中华医学会临床医学科研专项资金资助项目(07010210029)
  • 相关文献

参考文献26

  • 1孙娴雯,李庆云,顾淑一,万欢英.糖皮质激素治疗慢性阻塞性肺疾病的现状与展望[J].中华结核和呼吸杂志,2009,32(4):292-294. 被引量:22
  • 2Barnes P J. Reduced histone deacetylase in COPD: clinical implications. Chest, 2006, 129. 151 -155.
  • 3de Ruijter A J, van Gennip A H, Caron H N, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. BiochemJ, 2003, 370: 737-749.
  • 4Hu E, Dul E, Sung C M, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J PharmacolExpTher, 2003, 307: 720-728.
  • 5Guardiola A R, Yao T P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem, 2002, 277. 3350-3356.
  • 6Ito K, Ito M, Elliott W M, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N EnglJ Med, 2005, 352:1967- 1976.
  • 7Barnes P J. Histone deaeetylase-2 and airway disease. Ther Adv Respir Dis, 2009, 3; 235-243.
  • 8Barnes P J, Adcock I M. Glucocorticoid resistance in inflammatory diseases. Lancet, 2009, 373: 1905-1917.
  • 9Tonello A, Poli G. Molecular mechanisms of corticosteroid resistance. Chest, 2009, 135: 585-586.
  • 10Barnes P J. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol, 2009, 71. 451-464.

二级参考文献28

  • 1王晖,王伟,徐少华,张颖,黄河.吸入糖皮质激素对不同分型COPD气道炎症和重建的影响[J].中国老年学杂志,2007,27(5):466-468. 被引量:11
  • 2GOLD Executive Committee [ DB/OL 1. Guidelines: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2008 [ 2008-12-10 ] . http:// www. goldcopd, org/Guidelineitem, asp? 11 = 2&12 = 1&intld = 2003.
  • 3Quon BS, Gan WQ, Sin DD, et al. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest ,2008,133:756-766.
  • 4Sayiner A, Aytemur ZA, Cirit M, et al. Systemic glucocorticoids in severe exacerbations of COPD. Chest ,2001,119:726-730.
  • 5de Jong YP, Uil SM, Grotjohan HP, et al. Oral or Ⅳ prednisolone in the treatment of COPD exacerbations: randomized, controlled, double-blind study. Chest, 2007,132 : 1741-1747.
  • 6Mehic B. The role of inhalatory corticosteroids and long acting beta ( 2 ) agonists in the treatment of patients admitted to hospital due to acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Bosn J Basic Med Sci,2007,7:352-357.
  • 7Man SF, Sin DD. Inhaled corticosteroids in chronic obstructive pulmonary disease : is there a clinical benefit? Drugs, 2005,65 : 579-591.
  • 8Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest,2007,131:682-689.
  • 9Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med,1999,340 : 1948-1953.
  • 10Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax, 2005, 60:992 -997.

共引文献21

同被引文献11

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部